Investors

Press Releases

Date Title View
Toggle Summary Tetraphase Presents New Clinical and Preclinical Data for Novel Antibiotic TP-434 at 2010 ICAAC
Data Shows TP-434 Has Potential as First-line, Broad-spectrum Antibiotic for Treatment of Gram-negative and Multidrug-resistant Infections<br> Additional Data Shows TP-434 as an Orally Effective Antibiotic
View HTML
Toggle Summary Tetraphase to Present Extensive Data on Novel Broad Spectrum Antibiotic TP-434 at ICAAC
-Includes Oral Presentation and 12 posters-
View HTML
Toggle Summary Tetraphase Closes $45 Million Series C Financing. Company to advance novel antibiotics into clinical development to address serious drug-resistant, Gram-negative infections
Tetraphase Closes $45 Million Series C Financing. Company to advance novel antibiotics into clinical development to address serious drug-resistant, Gram-negative infections Tetraphase Closes $45 Million Series C Financing. Company to advance novel antibiotics into clinical development to address
View HTML
Toggle Summary Tetraphase Announces Participation in Session on New Treatments for Multidrug-Resistant Gram-Negative Bacteria at 2010 BIO International Convention
Tetraphase Announces Participation in Session on New Treatments for Multidrug-Resistant Gram-Negative Bacteria at 2010 BIO International Convention Tetraphase Announces Participation in Session on New Treatments for Multidrug-Resistant Gram-Negative Bacteria at 2010 BIO International Convention
View HTML
Toggle Summary Tetraphase Pharmaceuticals Completes Series B Financing to Support the Advancement of Novel Antibiotic Drug Candidates
Raises $10M to close first tranche of $25M Financing
View HTML
Toggle Summary Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 Watertown, MA  –  September 10, 2009  –  Tetraphase Pharmaceuticals Inc., a biopharmaceutical company capitalizing on breakthrough
View HTML
Toggle Summary Tetraphase Pharmaceuticals Completes Series A Financing to Support the Advancement of Breakthrough Synthetic Chemistry Platform Raises $15M to close second tranche of $25M Financing
Tetraphase Pharmaceuticals Completes Series A Financing to Support the Advancement of Breakthrough Synthetic Chemistry Platform Raises $15M to close second tranche of $25M Financing Tetraphase Pharmaceuticals Completes Series A Financing to Support the Advancement of Breakthrough Synthetic
View HTML
Toggle Summary Tetraphase Pharmaceuticals Formed to Advance Breakthrough, Harvard-Developed Synthesis Technology for New Antibiotics to Treat Drug-Resistant Bacterial Infections
Harvard University<br> Office of Technology Development
View HTML